Additional Information

Description

Tazicef 1g vial is an injectable formulation containing the active ingredient cefoperazone, a third-generation cephalosporin antibiotic. It is indicated for the treatment of various bacterial infections, including those of the respiratory tract, urinary tract, skin and soft tissues, and intra-abdominal infections. Cefoperazone exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa.

Cefoperazone works by inhibiting bacterial cell wall synthesis, leading to bacterial cell lysis and death. It achieves this by binding to penicillin-binding proteins (PBPs) on the bacterial cell membrane, which disrupts the cross-linking of peptidoglycan chains, a crucial component of the bacterial cell wall.

The medication is administered intravenously or intramuscularly, depending on the severity and type of infection. The dosage and duration of treatment are determined based on the patient’s condition, response to therapy, and susceptibility of the infecting organisms. Healthcare providers must monitor patients for potential side effects such as gastrointestinal disturbances, allergic reactions, and alterations in liver or renal function.